176 related articles for article (PubMed ID: 34957158)
1. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.
Mulder J; Verjans R; Verbaanderd C; Pean E; Weemers J; Leufkens HGM; Pignatti F; de Boer A; Voest EE; Stoyanova-Beninska VV; Pasmooij AMG
Front Med (Lausanne); 2021; 8():790782. PubMed ID: 34957158
[TBL] [Abstract][Full Text] [Related]
2. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
3. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
5. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
6. Requirements on efficacy of herbal medicinal products.
Claeson P
J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782
[TBL] [Abstract][Full Text] [Related]
7. More medicines for children: impact of the EU paediatric regulation.
Nordenmalm S; Tomasi P; Pallidis C
Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
[TBL] [Abstract][Full Text] [Related]
8. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
9. Extensions of indication throughout the drug product lifecycle: a quantitative analysis.
Langedijk J; Whitehead CJ; Slijkerman DS; Leufkens HG; Schutjens MH; Mantel-Teeuwisse AK
Drug Discov Today; 2016 Feb; 21(2):348-55. PubMed ID: 26657087
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
11. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
12. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
Pignatti F; Aronsson B; Vamvakas S; Wade G; Papadouli I; Papaluca M; Moulon I; Le Courtois P
Crit Rev Oncol Hematol; 2002 May; 42(2):123-35. PubMed ID: 12007970
[TBL] [Abstract][Full Text] [Related]
14. European regulatory use and impact of subgroup evaluation in marketing authorisation applications.
Tanniou J; Teerenstra S; Hassan S; Elferink A; van der Tweel I; Gispen-de Wied C; Roes KCB
Drug Discov Today; 2017 Dec; 22(12):1760-1764. PubMed ID: 28943304
[TBL] [Abstract][Full Text] [Related]
15. Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.
Refalo N; Chetcuti D; Tanti A; Serracino-Inglott A; Borg JJ
Saudi Pharm J; 2017 Feb; 25(2):280-289. PubMed ID: 28344480
[TBL] [Abstract][Full Text] [Related]
16. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
17. Current situation and evolution of the availability of drugs in the paediatric population in Spain.
Paradas-Palomo JD; Yunquera-Romero L; Gallego-Fernández C
Farm Hosp; 2024; 48(3):122-128. PubMed ID: 37612184
[TBL] [Abstract][Full Text] [Related]
18. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
[TBL] [Abstract][Full Text] [Related]
19. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.
Mulder J; Teerenstra S; van Hennik PB; Pasmooij AMG; Stoyanova-Beninska V; Voest EE; de Boer A
ESMO Open; 2023 Apr; 8(2):101209. PubMed ID: 37054504
[TBL] [Abstract][Full Text] [Related]
20. Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union.
Manellari S; Musazzi UM; Rocco P; Minghetti P
Int J Pharm; 2023 Jul; 642():123193. PubMed ID: 37394157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
